Momentum Builds in Denosumab Osteoporosis Market with New Launches and Pending Approvals Approval Status Updates and New Study Data Emphasized in Q3 2025 Multiple Myeloma Market

During Q3 2025, the denosumab in osteoporosis market centered on regulatory milestones and product launches of Prolia biosimilars, while the originator promoted its experience to a broad range of consumers.

Henlius and Organon announced the approval of Bildyos in the US and EU markets.

Biocon Biologics announced that its biosimilar, Bosaya, was granted a provisional interchangeability designation, along with FDA approval.

Fresnius introduced its denosumab biosimilars and featured the “Step Forward” campaign for Connexxence.

Teva’s Prolia biosimilar candidate was accepted for review by the FDA and EMA.

Hikma and Gedeon Richter received FDA approval for their denosumab biosimilars, emphasizing the products’ similarity and improved affordability.

Sandoz launched a new version of Jubbonti’s “Set the Stage” campaign and positioned its potential for cost savings amid rising Prolia prices.

Amgen educated men and women about osteoporosis risk factors through multilingual Prolia materials.

As part of Celltrion’s denosumab biosimilars launch, Stoboclo’s “Help Along the Way” theme premiered.